Liver Int

• 

  Publication Venue For

  • Relationship between three commonly used non-invasive fibrosis biomarkers and improvement in fibrosis stage in patients with non-alcoholic steatohepatitis..  39:924-932. 2019
  • The influence of drug properties and host factors on delayed onset of symptoms in drug-induced liver injury..  39:401-410. 2019
  • Expanding our toolkit to better identify drug-induced liver injury in electronic medical records..  38:585-587. 2018
  • Associations of gender and a proxy of female menopausal status with histological features of drug-induced liver injury..  37:1723-1730. 2017
  • The diversity and plasticity of adult hepatic progenitor cells and their niche..  37:1260-1271. 2017
  • Steatohepatitis and liver fibrosis are predicted by the characteristics of very low density lipoprotein in nonalcoholic fatty liver disease..  36:1213-1220. 2016
  • Liver injury from nonsteroidal anti-inflammatory drugs in the United States..  36:603-609. 2016
  • Reliability of causality assessment for drug, herbal and dietary supplement hepatotoxicity in the Drug-Induced Liver Injury Network (DILIN)..  35:1623-1632. 2015
  • Plasma Pro-C3 (N-terminal type III collagen propeptide) predicts fibrosis progression in patients with chronic hepatitis C..  35:429-437. 2015
  • Diabetes mellitus and advanced liver fibrosis are risk factors for severe anaemia during telaprevir-based triple therapy..  34:1018-1024. 2014
  • Association of age-dependent liver injury and fibrosis with immune cell populations..  33:1175-1186. 2013
  • Associations of depression, anxiety and antidepressants with histological severity of nonalcoholic fatty liver disease..  33:1062-1070. 2013
  • Macrophage-derived Hedgehog ligands promotes fibrogenic and angiogenic responses in human schistosomiasis mansoni..  33:149-161. 2013
  • Management of severe acute to fulminant hepatitis B: to treat or not to treat or when to treat?.  32:544-553. 2012
  • IL28B: relevance extended to hepatitis B virus or limited to interferon-based therapies in hepatitis C virus?.  31:1068-1070. 2011
  • Early prediction of sustained virological response at day 3 of treatment with albinterferon-alpha-2b in patients with genotype 2/3 chronic hepatitis C..  29:1350-1355. 2009
  • Genetic differences in oxidative stress and inflammatory responses to diet-induced obesity do not alter liver fibrosis in mice..  29:1262-1272. 2009
  • Sustained viral response after interferon-based therapy in chronic hepatitis C: more evidence to support a life-long cure..  29:481-482. 2009
  • Hepatic fat and adenosine triphosphate measurement in overweight and obese adults using 1H and 31P magnetic resonance spectroscopy..  28:675-681. 2008